Skip to main content

OncoMethylome Sciences Nets $11.6M in Private Placement

NEW YORK (GenomeWeb News) — OncoMethylome Sciences has raised €8.4 million ($11.6 million) by selling 1.3 million new shares at €6.29 a share to three investors in a private placement, the cancer biomarker company said today.
 
The company plans to use the funding to continue to develop biomarkers for use in companion diagnostic tests, cancer detection, and treatment.
 
The investment, which accounts for a 10.1 percent stake in the new company, came from AGF Private Equity, APG Investments, and Fortis Investments Management. AGF bought a 6 percent stake in OncoMethylome, while APG Investments and Fortis acquired a 2.4 percent and 1.7 percent stake in the company, respectively.
 
Liege, Belgium-based OncoMethylome noted that it currently has no financial debt, and as of the date of the placement it holds roughly €30 million in cash and cash equivalents.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.